| |
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now. 
|
|
Today's Big NewsNov 22, 2022 |
| By Nick Paul Taylor Pfizer’s $1 billion bet on Arvinas’ protein degradation technology has delivered phase 2 data. After a publication snafu, Arvinas posted the breast cancer results ahead of schedule—and revealed one partial response among 35 patients at its phase 3 dose. |
|
|
|
By Max Bayer Gamida Cell will need to wait a while longer to know whether regulators greenlight its stem cell transplant therapy, with the FDA extending the review period for the approval application by three months. The company said recent data provided to the FDA was considered a major amendment, prompting the extension. |
By James Waldron With all the talk of drugmakers cutting pipelines and laying off staff, it’s good to occasionally report on some investment back into the sector. For Novo Nordisk, that means investing 5.4 billion Danish kroner ($74 million) to boost R&D manufacturing needed for its clinical trials. |
By James Waldron Only two months after a ruthless restructuring saw the company cut staff by 70% and focus much of its remaining resources on the preterm labor treatment ebopiprant, ObsEva is now selling off that potential therapy as well. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
By Nick Paul Taylor Khondrion’s mitochondrial disease candidate has missed the mark in a phase 2b clinical trial. But the Dutch biotech, clutching post hoc analyses and long-term follow-up data, plans to advance into the next stage of development anyway in the belief the totality of the evidence supports further work. |
By Max Bayer FogPharma has raised nearly $300 million over its last two fundraising rounds, announcing that it had netted $178 million in a series D. The money will be used to continue advancing the company's pipeline as its lead asset nears the clinic. |
By Helen Floersh An antibody found in pregnant women who were infected with Zika but didn’t pass the virus on to their fetuses appears to protect mice from the virus and even suppress it to the point that it’s undetectable in their blood. |
By Fraiser Kansteiner On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Teva CEO Kåre Schultz, who is hanging up his CEO hat to retire on Dec. 31. The news comes a little more than two weeks after Teva said it was looking for Schultz’s replacement. |
By Andrea Park More than half of Teleflex's restructuring costs—between $18 million and $22 million—will come from termination benefits paid out to laid-off employees. |
By Nick Paul Taylor Erytech is stepping up its focus on the drug delivery applications of its preclinical extracellular vesicles, pivoting toward the platform after halting development of its lead asset in the wake of a phase 3 flop. |
By Robert King Leaders of the House Ways and Means Committee are pressing the Biden administration to change a rule that implements the arbitration process as part of a ban on surprise medical bills. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report. |
|
|---|
|
|
|
Tuesday, November 29, 2022 | 2pm ET / 11am PT Process development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise in a field that is very dynamic and accelerating fast. Outsourcing gives you direct access to infrastructure, experience, and a team who has done this before and can quickly generate meaningful data taking the guesswork out of process development. Register now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
